Cargando…
Engineering a HER2-CAR-NK Cell Secreting Soluble Programmed Cell Death Protein with Superior Antitumor Efficacy
A new therapy strategy for relapsing patients who have received trastuzumab treatment urgently needs to be explored. HER2-specific chimeric antigen receptor (CAR)-expressing NK cells are being rapidly developed for solid tumor therapy, as they have many advantages over HER2-CAR-T cells. Endogenous s...
Autores principales: | Xia, Wenjiao, Chen, Jiaxin, Hou, Wenqing, Chen, Junsheng, Xiong, Ying, Li, Hongyan, Qi, Xin, Xu, Hui, Xie, Zuoquan, Li, Mingfeng, Zhang, Xiaomin, Li, Jing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094803/ https://www.ncbi.nlm.nih.gov/pubmed/37047817 http://dx.doi.org/10.3390/ijms24076843 |
Ejemplares similares
-
Arming NK cells with enhanced antitumor activity: CARs and beyond
por: Oberoi, Pranav, et al.
Publicado: (2013) -
Cycloartenyl ferulate improves natural killer (NK) cell immunity against cancer by binding to IFNγ receptor 1
por: Li, Mingfeng, et al.
Publicado: (2023) -
NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness
por: Bachiller, Mireia, et al.
Publicado: (2021) -
A Soluble NK-CAR Mediates the Specific Cytotoxicity of NK Cells toward the Target CD20(+) Lymphoma Cells
por: Liu, Rongjiao, et al.
Publicado: (2022) -
Superior Expansion and Cytotoxicity of Human Primary NK and CAR-NK Cells from Various Sources via Enriched Metabolic Pathways
por: Yang, Yan, et al.
Publicado: (2020)